CRISPR patent landscape Sample-2016-01 20160208 · 2016. 2. 3. · CRISPR patent landscape - SAMPLE 5 ©2014-2016 Temporal distribuGon of patent ﬁlings by type of applicants (2004-2015)

CRISPR patent landscape - SAMPLE ©2014-2016 IPStudies SARL

CRISPR PATENT LANDSCAPE

January 2016

Intangibleassetsdeservecloserscru2ny

CRISPR patent landscape - SAMPLE ©2014-2016

Copyright

•  Unless otherwise specified, all content included on this document, such astext, graphics, logos, bu8on icons, images, audio and video clips, digitaldownloads, data compila:ons, and so;ware, including but not limited toIPStudies surveys, is the property of IPStudies SARL and protected byinterna:onalcopyrightlaws.

•  You agree not to copy, reproduce, duplicate, sell, resell, or exploit for anycommercialpurposes,anypor;onofthiscontent.

•  Youmaynotre-useand/orextractpartofthiscontentoutsideofyourlegalen;ty, ins;tu;onal or corporate environment without IPStudies’s expressconsentinwri;ng.

2


Our team

3

CorinneLEBUHAN,PhDICTExpertIPStrategy&Management

•  FundedIPStudiesin2010tohelpSwiss&EUhigh-techSMEsdevelopandexecutetheirIPvalua:onplansusingthelatestpatentanaly:cstoolsandtrends

•  15yearsexperienceinIPstrategyandmanagement–formerVPKnowledgeManagementofNagravision-KudelskiGroup,inchargewithpatents(200families),standards,R&Dcollabora:ons,licensingandtechnicalpublica:onsporZolios

•  Teachesinterna:onallicensingprac:cesandIPstrategyatIEEPI–EUHorizon2020expertonInnova:oninSMEs2013-2015

•  ICTTechnologyExpertforvariouslicensingfacilitatorsandaggregatorsinFrance,GermanyandtheUS

•  Universitypostgraduateinmanagementofinnova:onandintellectualproperty(UniversityofStrasbourg,2008),PhDinCommunica:onsScience(EPFL,1998),MsCinElectricalEngineering(INSARennes,1994)

•  ExperiencedwithPatbase,EPO/RegisterPlus,USPTO/PAIR•  Interna:onalnetworkofIPprac::onersandlicensingmanagers-

MemberLES,IEEE,AROPI,AAIEEPI

FabienPALAZZOLI,PhDLifeSciencesExpertPatentAnalysis&Landscapes

•  JoinedIPStudiesin2013todeveloptheIPanaly:csofferinginlifesciences&biotechnology

•  9+yearsexperienceintechnologytransfers,patentmapping/landscapingandFTO-drivenresearchintelligencefortheFrenchpublicsectorandbiotechSMEs-formerIPanaly:cssalesmanagerforFISTSA,theCNRStechnologytransferoffice

•  Author/co-authorof18scien:ficandtechnicalpublica:ons/communica:ons,aswellasonebookchapter

•  Lifesciencespatentanalystforvariousbiotech/medtechSMEsinSwitzerlandandinEurope

•  PhDinLifeSciences(Exploita:onofpatentinforma:oninapublicresearchlaboratory:iden:fica:onoftechnologicalnichesinbioproduc:onandgenetherapy,UniversityofTours,2011),MsCinBiotechnologyandLaw(UniversityofTours,2007)

•  ExperiencedwithOrbit,Patbase,Intellixir,patentofficesdatabases

•  Interna:onalnetworkofpatentinforma:onanalysts


Table of contents

4

•  Methodology•  OveralltrendsoftheCRISPRpatentdatabase

•  Temporaldistribu:onofpatentfilings(2004-2015)•  Temporaldistribu:onofpatentfilingsbytypeofapplicants(2004-2015)•  Worldmapofpriorityfilings•  Temporaldistribu:onofpriorityfilings(2004-2015)•  Worldmapofpatentextensions•  Mainpatentapplicants•  Temporaldistribu:onoffilingsofapplicants•  Co-filingsbetweenapplicants

•  BreakdownoftheCRISPRpatentdatabase•  BreakdownbyClaimcoverageofpatentfamilies

•  BreakdownofthepatentporZolio•  Temporaldistribu:onoffilings•  Posi:oningofapplicants

•  BreakdownbyComponents•  BreakdownofthepatentporZolio•  Temporaldistribu:onoffilings•  Posi:oningoftheapplicants

•  BreakdownbyChimericproteins•  BreakdownofthepatentporZolio•  Temporaldistribu:onoffilings•  Posi:oningofapplicants

•  Mainforwardcitedpatentfamilies•  Appendices–licensingannouncements,affilia:onmappingofplayerspresentinthepatentlandscape


Temporal distribuGon of patent filings by type of applicants (2004-2015)

Ø  290filingsbyins:tu:onalapplicants(59.3%),Ø  154filingsbyindustrialapplicants(31.5%),Ø  32filingsbyindividualinventors(6.5%),Ø  13co-filingsbetweenindustrialapplicantsandins:tu:onalapplicants(2.7%).Ø  Theyears2014and2015arenotcompleteduetothedelayofpublica:onof18months.

489patentfamilies


Main patent applicants/assignees (≥ 3 patent families)

Ins2tu2onalapplicants

Industrialapplicants

Ø  Affiliates&subsidiarieshavebeengatheredundertheirparentcompany(DaniscowithDuPont…).Co-filingsarecounted for each co-owner: a patent applica:on co-filed between theMIT, the Harvard University and theBroadIns:tuteiscountedonceforeachco-applicant.

Ø  Withinthe38mainapplicants,27areins:tu:onalapplicantsand11areindustrialapplicants.Ø  ThepatentporZolioofDuPontcompriseshistoricalpatentfamiliesonCRISPRsequencesdealingwiththetyping

ofbacterialstrains,cultureswithimprovedphageresistanceandapplica:onsforpreparingfood.


Co-filings between applicants/assignees

7

Ø  Theco-filingmapshowstheco-filingsbetweenapplicants,resul:ngeitherfromeitherajointR&Dprojectoralaterassignmentagreementasregisteredinpatentoffices.

Numberofpatentfamilies

inthepor9olio

Co-filing(s)betweenthetwoapplicants


Licensor Scope Licensee Date

Toolgen

Worldwidelicense&sublicensesrightsforresearchapplica:onsincludingthedevelopmentandsaleofreagents,celllines,andanimalmodels,aswellasrightsforhighthroughputscreening,diagnos:cs,andbioproduc:on.ToolGenretainsitsrightsinbroadareasincludinghighthroughputscreening,diagnos:cs,bioproduc:on,plantbiotechnologyandgene/celltherapy.

ThermoFisherScien:fic 2015/03

DuPont

Thecross-licenseenablesCariboutodevelopandu:lizeCRISPR-Castechnologyforproductdevelopmentinmul:plefieldsincludinghumanandanimaltherapeu:cs,diagnos:cs,industrialbiotechnology,researchtools,andcertainagriculturesegments.TheDuPontlicensetoCaribouincludesrightstotheCas9-mediatedgenomeedi:ngintellectualpropertyownedbyVilniusUniversityandexclusivelylicensedtoDuPont.

CaribouBiosciences 2015/10

CaribouBiosciences

Mul:-facetedagreementincludesthecross-licensingofkeyintellectualproperty,aresearchcollabora:on,andfinancialinvestmentsbyDuPontinCaribou,adeveloperofCRISPR-Castechnologies.

DuPont 2015/10

CrisprTherapeu:cs

$105millionupfront—$75millionincash,$30millionequityinvestment-futuredevelopment,regulatoryandsalesmilestonesofupto$420millionforeachofuptosixCRISPR-Cas9-basedtreatmentsforwhichVertexhasagreedtolicenseexclusivedevelopmentrights.Royal:esonfuturesales.

Vertex 2015/10

ERSGenomicsNon-exclusivelylicensedpatentsrelatedtoCRISPR-Cas9genome-edi:ngtechnologytoRegeneronPharmaceu:calsforuseindrugdiscoveryanddevelopment

Regeneron 2015/11

8

License announcements – SAMPLE PAGE (4)


Breakdown of the CRISPR patent database

•  Genomeedi:ngwithEN

•  Modula:onofgeneexpression

•  Otherapplica:on

•  Therapeu:capplica:on

•  Bioproduc:on

•  Drugscreening

•  Gene:callymodifiedcell

•  Transgenicanimal

•  Transgenicplant

Applica;ons

•  Humancell/subjet

•  Mammaliancell/organism

•  Otheranimalcell/organism

•  Plantcell/organism

•  Fungi-algae-yeast

•  Eukaryo:ccell/organism

•  Prokaryo:ccell

•  Otherorganism

•  Undefinedcell/organism

Cell/Organism

•  Nuclease

•  ZFNuclease-ZFD

•  Meganuclease

•  TALENuclease-TALEP

•  NA-targe:ngRNA

•  CRISPR-assoc.protein

•  CRISPR-Cassystem

•  Otherchimericprotein

•  Vector

•  CRISPRsequence

‘Moleculartools’

‘CLAIMCOVERAGE’OFPATENTFAMILIES

The489patentfamilieshavebeensystema;callyreviewedandclassifiedbyourgenomicsexpert

Ø  A patent family can be classified in several categories (e.g. ‘Genome Edi;ng with EN’ and ‘Therapeu;capplica;on’and‘Humancell’and‘CRISPR-Cassystem’…).


Breakdown of the CRISPR patent database

COMPONENTS CHIMERICPROTEINS

Chimericnucleases•  Undefinednuclease

•  ZFNuclease

•  Meganuclease

•  TALENuclease

•  RNA-GuidedNuclease

•  Otherchimericnuclease

Otherchimericproteins

•  CRISPR-associatedprotein

•  mutatedCas-nickase

•  dCas

•  Cas9

•  mutatedCas9-nickase

•  dCas9

•  OtherCas

•  OthermutatedCas

•  NA-targe:ngRNA

•  gRNA

•  crRNA

•  tracrRNA

•  psiRNA

•  Nuclease

•  Meganuclease

•  Integrase

•  Recombinase

•  Repressor-Ac:vator

•  Acetyltransferase

•  Deacetylase

•  Methyltransferase

•  Demethylase

•  Kinase

•  Othercataly:cdomain

•  Undefinedcataly:cdomain

Ø  A patent family can be classified in several categories (e.g. ‘Genome Edi;ng with EN’ and ‘Therapeu;capplica;on’and‘Humancell’and‘CRISPR-Cassystem’…).

The489patentfamilieshavebeensystema;callyreviewedandclassifiedbyourgenomicsexpert


Breakdown by Claim coverage of patent families Breakdown of the patent porXolio

EN=EngineeredNucleasesNA-targe2ngRNA=NucleicAcid-targe2ngRNA,guideRNA…

Applica2ons Cell/Organism ‘Coveredmoleculartools’


Breakdown by Claim coverage of patent families PosiGoning of the main applicants/assignees (≥ 5 patent families)

Distribu;onofapplicantswithatleast4patentfamiliesintheirpatentporZolioOrderourfullpatentlandscapetoaccesstheapplicantnames


Breakdown by Components PosiGoning of the main applicants/assignees (≥ 4 patent families)



Breakdown by Chimeric proteins PosiGoning of the main applicants/assignees (≥ 4 patent families)



Further analyGcs for your specific needs with the online database

•  ZoomonpatentporZoliosofspecificapplicants

•  Zoomonpatentsfiledinacountry/region(US,EP,CN…),withina:meperiod

•  Zoomonpatentscoveringanapplica:on,adedicatedtechnology,aspecifica:onorafunc:onalsubset

•  Linktoonlinepatentofficeregisterstoreviewlatestlegalstatus

15


Access to the interacGve “navigate, zoom, click and show patent” database

16

4

1

2

3


Order

17

This is only a sample report with par:al data. Our fullofferincludes:•  ananalysisofthepatentlandscape,covering489patentfamilies,worldwide•  asynthesisofIPstrategyfindings,tovisualizekeytrendsintermsofpatentapplicants,collabora:onnetworks,compe:tortechnologyposi:oning,keyinventorsandR&Dwhitespacesoutofthelandscape•  anon-lineaccesstothe489patentfamiliesset,soyoucanvisualize,navigate,focusandextractthemostrelevantpatentdataaccordingtoyourspecificneeds.

[email protected]+41797875746

Documents

CRISPR patent landscape Sample-2016-01 20160208 · 2016. 2. 3. · CRISPR patent landscape - SAMPLE 5 ©2014-2016 Temporal distribuGon of patent ﬁlings by type of applicants (2004-2015)